Mark H. Remus

Clients trust Mark to solve their patent disputes quickly, efficiently, and strategically. He has served as lead counsel on numerous patent infringement litigation matters, and he has successfully represented clients in jury trials, bench trials, and appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court.  Intellectual Asset Management (IAM) magazine writes that Mark is “[a]lways one of the best lawyers in the courtroom, he has an even temperament for litigation and is precise in everything he does,” calling him “quite a force to be reckoned with.” Clients recognize Mark for being “always well-prepared and conscientious” and “tough when the situation requires it.” 

Mark has extensive experience with pharmaceutical litigation under the Hatch-Waxman Act. He has advised clients on a wide range of drug products and technologies, including new chemical entities, complex formulations, polymorphs, methods of treatment and extended release formulations. Mark is also experienced in FDA practice and strategy related to generic pharmaceutical products, including controlled correspondence, citizen petitions, suitability petitions and labeling carve-outs. 

Mark also has experience protecting and defending other technologies, including medical devices, communications networks, cellular telephony, LCD panels, oil drilling equipment, wind turbines, electrical connectors, and mechanical devices. He is a frequent speaker and author on current topics in patent law.

Mark consistently has been named by publications and in lists that honor attorney achievement. Mark is listed in The Best Lawyers in America© 2016 and in the IAM Patent 1000 2015 and 2016The World’s Leading Patent Professionals, and was ranked in the top 100 attorneys in the 2015 Illinois Super Lawyers list. Mark is an LMG Life Science Star (2015) and is listed in Managing Intellectual Property's - Expert Guides: Guide to the World's Leading Patent Law Practitioners (2015). In 2006 he was named one of Forty Illinois Attorney Under 40 to Watch by Super Lawyers Rising Stars.

  • J.D., cum laude
    University of Illinois College of Law, 1997
  • B.S., Chemical Engineering, with distinction
    University of Illinois, 1994
Bar Admissions
  • Supreme Court of the United States
  • U.S. Court of Appeals, Fed. Cir.
  • U.S. Dist. Court, N.D. Illinois
  • U.S. Dist. Court, N.D. Illinois, Trial Bar
  • U.S. Patent & Trademark Office
Experience | Overview
  • Mark led a trial team through a seven-week bench trial that resulted in the district court invalidating a patent on a $1 billion per year drug. The district court’s decision was affirmed on appeal.
  • Mark successfully argued before the Federal Circuit to reverse a decision by the Patent Trial and Appeal Board that the target patent was valid. This was only the second time that the Federal Circuit reversed a validity finding by the PTAB in an inter partes reexamination.
  • After a two-week jury trial, Mark’s trial team achieved a complete victory for his patent owner-client on multiple counts of patent and trademark infringement. The district court subsequently found the infringer in contempt of a post-trial injunction and awarded attorney’s fees for willful infringement. The total judgment was over $12 million on just $2 million in accused sales. In awarding attorney’s fees, the district court noted that the “high level of Plaintiffs’ attorneys’ trial practice skills was a significant factor in achieving a favorable result for the Plaintiffs.”
  • In a case that reached the Supreme Court, Mark and his colleagues represented a worldwide offshore drilling contractor in a patent infringement case involving an offshore drilling apparatus.  The case made two trips to the Federal Circuit Court of Appeals, and then settled on appeal to the Supreme Court after to the Court referred the case to the Solicitor General for review and comment.
  • Panelist, "Defensive Strategy 2.0: Facing a Better Prepared Plaintiff," CenterForce IP Strategy Summit, Seattle, Washington, May 3, 2017
  • Panelist, "Parallel Proceedings Moot Court: District Court and PTAB Mock Pharmaceutical Patent Invalidity Hearing," Brinks Sponsoring ACI Paragraph IV Disputes, New York, NY, April 25, 2016
  • "2016 IP Developments," Brinks Webinar,  January 28, 2016
  • Panelist, FRCP 16 and 26: Brand and Generic Viewpoints on Scheduling Orders, Protective Orders and ESIs in a Hatch-Waxman Setting | Paragraph IV Disputes, Chicago, Illinois (September 30, 2015)
  • Presenter, Litigation Issues | Fundamentals of Patent Prosecution 2015: A Boot Camp for Claim Drafting & Amendment Writing, Chicago, Illinois (May 14, 2015) Speaker, Limelight v. Akamai: Assessing Its Impact on Method of Treatment Patents and Section viii Label Carve Outs | Paragraph IV Disputes Conference, New York, New York (April 27–28, 2015)
  • Panelist, Business Method Patents Following Alice v. CLS Bank | Tenth Annual JTIP Symposium, Chicago, Illinois (March 6, 2015)
Representative Matters
  • Representation of pharmaceutical companies in Hatch-Waxman litigation relating to a wide range of drug products, including: budesonide, caspofungin, cefdinir, doxercalciferol, galantamine, levoceterizine, metformin, repaglinide, ropivacaine, venlafaxine and zolpidem.
  • Successful defense of a global supplier of generic pharmaceuticals against request for temporary restraining order and preliminary injunction by Abbott and Astellas over patents relating to the antibiotic Omnicef® and generic cefdinir. Abbott Labs v. Sandoz Inc. (N.D. Ill. 2007; Fed. Cir. 2008; S.Ct. 2009).
  • Representation of a medical laboratory in a patent infringement suit involving medical devices. Advance DX, Inc. v. Healthpoint Diagnostix, Inc. (N.D. Ill. 2013).
  • Successful defense of a developer and manufacturer of aerosol drug delivery devices and asthma management products against motion for preliminary injunction in litigation relating to patent for valved holding chambers. PRE Holding Inc. v. Monaghan Medical Corp. (E.D. Va. 2009).
  • Representation of a global leader in energy-management solutions in a two-week trial, in which a jury found in favor of client on all counts. The court entered a final judgment in excess of $14.5 million. Intermatic Inc. v. Lamson & Sessions Corp. (N.D. Ill. 1999, Fed. Cir. 2000, S.Ct. 2003).
  • Defense of a drilling rig operator in patent litigation relating to patents for offshore drilling rigs and methods of drilling offshore oil wells. Transocean Offshore Deepwater Drilling Inc. v. Maersk Contractors USA, Inc. (S.D. Tex. 2007; Fed. Cir. 2010).
  • Representation of a manufacturer of custom filtration and fluid control devices in a multi-year litigation over client's patent regarding needleless connectors for use in intravenous medical systems. Obtained a $7.3 million settlement in favor of client. Filtertek Inc. v. Alaris Medical Prods. (N.D. Ill. 2002).
  • Representation of an innovator of air-filled products in a two-week trial, in which a jury found in favor of client on all counts. The court entered a final judgment in excess of $12.9 million. Aero Products Int'l v. Intex Recreation Corp. (N.D. Ill. 2001; Fed. Cir. 2005).
Press Releases & Events
March 27, 2017
CHICAGO—Six attorneys and shareholders at intellectual property law firm Brinks Gilson & Lione have been selected for inclusion in Euromoney PLC’s 2017 Expert Guide to the World’s Leading Patent Law Practitioners: William H. ...
March 07, 2017

CHICAGO—Mark Remus, a shareholder and patent litigator at intellectual property law firm Brinks Gilson & Lione, presented “The Strategic Use of IPRs to Challenge Pharmaceutical Patents” at CPhI’s 6th Annual Pharma IPR Conference in Mumbai, India, on March 1, 2017...

March 01, 2017

On March 1, 2017, Mark Remus will be presenting on Inter Partes Review at the CPhI's 6th Annual Pharma IPR ...

February 09, 2017

CHICAGO—Twenty attorneys at intellectual property law firm Brinks Gilson & Lione have been named to the 2017 ...

January 03, 2017

CHICAGO—Brinks Gilson & Lione, one of the nation’s largest intellectual property law firms, ...

August 15, 2016

CHICAGO—Fifteen attorneys at Brinks Gilson & Lione, one of the largest intellectual property law firms in the United  ...

June 01, 2016

CHICAGO—National law firm Brinks Gilson & Lione is “at the top of the list” again this year for intellectual property according to IAM Patent 1000 2016—The World’s Leading Patent Professionals, Intellectual Asset Management (IAM) magazine's guide to leading private practice patent professionals and firms.

April 25, 2016
Mark Remus will participate in, "Parallel Proceedings Moot Court: District Court and PTAB Mock Pharmaceutical Patent Invalidity Hearing" This interactive session will illustrate the ins and outs of this balancing act through a mock ...
January 28, 2016
Join Brinks Gilson & Lione attorneys, Jim Sobieraj, Mark Remus, Amy Fix, Bill Frankel and Laura Beth Miller as they discuss the issues that will be front and center on the minds of Intellectual Property Departments and Attorneys in 2016, ...
January 25, 2016

CHICAGO—Intellectual property law firm Brinks Gilson & Lione—one of the nation’s largest IP boutiques ...

September 01, 2015
CHICAGO—Intellectual property law firm Brinks Gilson & Lione announced today that Mark H. Remus has rejoined the firm as a partner in its Chicago office. Remus is a seasoned trial lawyer who has served as lead counsel on numerous patent ...
  • Named, Euromoney Expert Guide to the World's Leading Patent Law Practitioners, 2017
  • Intellectual Asset Management, IAM Patent 1000, 2015-2016; IAM Patent Litigation: Illinois, 2013–2014
  • LMG Life Sciences, Life Science Star, 2012–2014
  • Illinois Super Lawyers, Intellectual Property Litigation, 2013–2017; Super Lawyers Rising Stars, 2008-2009, 2011-2012, Forty Illinois Attorneys Under 40 to Watch, 2006
  • Best Lawyers in America, 2016-2018
  • American Bar Association
  • American Intellectual Property Law Association
  • Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI)